Incyte | INCY

Stock Price
51.16
Daily Change
-0.62 -1.20%
Monthly
-9.54%
Yearly
-30.43%
Q2 Forecast
55.88
Peers Price Chg Day Year Date
ACAD Acadia Pharmaceuticals 16.32 -0.27 -1.63% -19.65% Apr/25
AGIO Agios Pharmaceuticals 31.67 0 0% 43.30% Apr/25
ALNY Alnylam Pharmaceuticals 143.70 -0.09 -0.06% -27.25% Apr/25
AMGN Amgen 269.42 -3.72 -1.36% 12.82% Apr/25
BIIB Biogen 202.49 0.36 0.18% -29.70% Apr/25
BMRN BioMarin Pharmaceutical 82.17 -9.07 -9.94% -11.65% Apr/25
BMY Bristol-Myers Squibb 44.70 -4.16 -8.51% -34.28% Apr/25
EXEL Exelixis 23.53 -0.18 -0.76% 27.53% Apr/25
GILD Gilead Sciences 65.07 -1.83 -2.73% -22.30% Apr/25
INCY Incyte 51.16 -0.62 -1.20% -30.43% Apr/25
IONS Ionis Pharmaceuticals 41.81 -0.65 -1.53% 16.95% Apr/25
LLY Eli Lilly 729.01 -8.11 -1.11% 93.75% Apr/25
MGNX MacroGenics 14.37 -1.33 -8.47% 110.70% Apr/25
MRK Merck 130.49 3.59 2.83% 15.04% Apr/25
MRNA Moderna 106.22 -2.79 -2.56% -18.75% Apr/25
NBIX Neurocrine Biosciences 137.73 -1.24 -0.89% 34.08% Apr/25
NOVN Novartis 89.35 -0.65 -0.72% -2.19% Apr/26
NVS Novartis 99.12 0.74 0.75% -3.34% Apr/25
PFE Pfizer 25.26 -0.97 -3.69% -34.61% Apr/25
PTCT PTC Therapeutics 25.49 0.28 1.11% -51.21% Apr/25
RARE Ultragenyx Pharmaceutical 43.85 -0.41 -0.93% 3.59% Apr/25
REGN Regeneron Pharmaceuticals 906.54 -16.99 -1.87% 16.52% Apr/25
SRPT Sarepta Therapeutics 127.41 3.16 2.54% 4.20% Apr/25
VRTX Vertex Pharmaceuticals 397.24 -3.35 -0.84% 22.87% Apr/25

Indexes Price Day Year Date
CCMP USND 15612 -100.99 -0.64% 31.70% Apr/25
SPX US500 5084 -23.21 -0.46% 22.95% Apr/26

Incyte Corp traded at $51.16 this Thursday April 25th, decreasing $0.62 or 1.20 percent since the previous trading session. Looking back, over the last four weeks, Incyte lost 9.54 percent. Over the last 12 months, its price fell by 30.43 percent. Looking ahead, we forecast Incyte Corp to be priced at 55.88 by the end of this quarter and at 52.74 in one year, according to Trading Economics global macro models projections and analysts expectations.

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.